Form 8-K DiaMedica Therapeutics For: May 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
DiaMedica Therapeutics Inc. (DMAC) Tops Q1 EPS by 2c
May 8, 2024 4:44 PM EDTDiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q1 EPS of ($0.14), $0.02 better than the analyst estimate of ($0.16).
For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.
... More